Resultados de la búsqueda 351-360 of 14502 for skin care

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part ...

  2. Hematología - Ensayos clínicos - Mayo Clinic

    ... treatment (refractory). Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Romidepsin and ...

  3. Foliculitis - Síntomas y causas - Mayo Clinic

    In: Taylor and Kelly's Dermatology for Skin of Color. ... In: Dermatology for the Primary Care Provider. ... In: Ferri's Fast Facts in Dermatology: A Practical ...

  4. Neurocirugía - Ensayos clínicos - Mayo Clinic

    Immunotherapy with monoclonal antibodies such as ipilimumab and nivolumab may help the body's immune system attack the cancer and may interfere with the ability ...

  5. Queratosis seborreica - Diagnóstico y tratamiento - Mayo Clinic

    Mayo Clinic; 2021. Kelly AP, et al., eds. Geriatrics. In: Taylor and Kelly's Dermatology for Skin of Color. 2nd ed. McGraw-Hill; 2016. https://accessmedicine.

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The pupose of this study is to evaluate whether or not selumetinib works just as well as the standard treatment with carboplatine/vincristine (CV) for subjects ...

  7. Untitled

    Page 1.

  8. Mayo Clinic pone a disposición de Carteret Health Care su conocimiento y experiencia

    William "Harvey" Case, director general de Carteret Health Care, comparte el valor de la colaboración clínica con Mayo Clinic y mantiene a los pacientes ...

  9. Salud del adulto Noticias de la Mayo Clinic

    Mayo Clinic Q and A: Self-care steps can keep your heart healthy during the holidays Dec. ... Skin cancer survivors: How to stay safe in the ... How to care for ...

  10. Hematología - Ensayos clínicos - Mayo Clinic

    ... treatment in patients with treatment-naive ALK-positive advanced NSCLC. Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg ...